疾病
前列腺癌Prostate cancer
前列腺癌 · ICD-10：C61 — Malignant neoplasm of prostate
关键数据
仅为已发布的数值。每个图块都会打开带有其来源、年份与口径的章节。
疾病详情
- 规范中文名
- 前列腺癌
- 英文名
- Malignant neoplasm of prostate
以中文写出的数值按来源原样引用。
又称
- 前列腺恶性肿瘤
- Prostate cancer
- PCa
治疗费用区间
以下每个区间都按一种计费口径发布：医保报销前。 来源未发布报销后数值，因此这里不展示。
| 治疗路径 | 费用区间 | 价格依据 | 数据年份 |
|---|---|---|---|
| 手术 | 42500 – 60000 CNY | 病种打包全包价 | 2020–2021 |
| 放疗 | 31000 – 70000 CNY | 项目价 | 2025–2026 |
| 化疗 | 15000 – 27000 CNY | 全病程例均 | 2015–2017 |
| 靶向 | 9000 – 79000 CNY | 项目价 | 2025 |
| 免疫 | 不适用 | 不适用 | — |
上方的条形共用同一刻度：每条从该行已发布的下限值起，到其上限值止。本页最高的上限值为 79000 CNY。每行保留自己的数据年份与口径。
该疾病的 5 个费用区间，来源见各行页面。
以中文写出的数值按来源原样引用。
五年生存
5 年生存率 71.1% 95% 置信区间 70.2–71.9
- 人群
- 总体（全分期合并）· 年龄标准化相对生存率
- 时期
- 2019–2021
- 发布机构
- 国家癌症中心
- 数值性质
- 估计值（混合法）
- 登记范围
- 281 个肿瘤登记处
- 分期数据可用性
- 未发布
以中文写出的数值按来源原样引用。
如何解读该数据。 它按全分期合并发布，因此是全国登记数据中所有人的平均值，而不是对某个人的预后。对多数癌症而言，确诊时的分期是生存差异背后最强的单一因素：通常，癌症发现得越早，生存率越高；发现得越晚，越低。不同癌症之间的比较也受到各自通常确诊早晚的影响，因此一个较低的数值本身并不意味着诊疗更差。
该数值是相对生存率：它把被诊断患此癌的人与一般人群中同年龄、同性别的人相比较，且为年龄标准化，因此它不是五年后仍存活患者所占的比例。它以估计值（混合分析）发布，因为登记报告存在滞后，故国家癌症中心对最近一段时期作了模型估计。作为参照，同一来源发布 2019–2021 年全部癌症合计的五年相对生存率为 43.7%。
在该疾病上有已发布记录的医院
依据官方公开数据来源筛选
这些医院依据官方公开数据来源筛选——复旦大学医院专科声誉排行榜、国家临床重点专科名单与国家临床医学研究中心——因此卡片上的每一行都可与其已发布的来源核对。这不是付费或推广位。
这些医院是如何筛选的
入选。当某疾病所归属的专科满足以下至少一项时，医院即被列入该疾病：在复旦大学医院专科声誉排行榜中有一个名次或提名；有一条 A、B 或 C 级的国家临床重点专科记录；或该专科有一个国家临床医学研究中心或国家重点实验室。JCI 认证仅作徽标展示；它绝不决定入选，也绝不决定排序。
排序。第 1 步：该专科在复旦榜中的第 1 至第 10 名。第 2 步：又一个复旦名次，或一个提名。第 3 步：一条 A 级国家临床重点专科。第 4 步：一条 B 级国家临床重点专科。第 5 步：该专科的一个国家临床医学研究中心或国家重点实验室，研究中心优先于实验室。第 6 步：一条 C 级国家临床重点专科——这是我们发布的一条没有独立官方来源的记录，因此排在其余之后。
平局。在同一步骤内：复旦名次更好的在前，其次重点专科等级更高者（A 先于 B，B 先于 C），再次省份，再次城市，最后医院名称——与医院目录所用的省—市—名称顺序相同。最多列出八家医院。
当名单较短时。五家及以上：列出前八家。三家或四家：全部列出，并有一个可展开的折叠区，把其余记录补至最多八条，每条都带其证据等级。一两家：同上，且该折叠区默认展开，并有一行说明有多少家医院有可靠的公开记录。没有：页面说明未找到可靠的公开记录，并链接到专科目录。绝不为了凑数而编造名次、机构或数量。
复旦排行榜是中国临床医生最广泛认可的医院专科声誉排行榜，由复旦大学医院管理研究所每年发布。
-
中国人民解放军总医院Chinese PLA General Hospital
复旦专科声誉排行榜 2023
- Urology #1 https://www.fdygs.com/news2023-1.aspx
已发表研究
- Dual Compartmentalization of GSTA4 Suppresses Ferroptosis to Drive Antiandrogen Resistance in Prostate Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026
- Association of robot-assisted radical prostatectomy with improved oncological outcomes in patients with oligometastatic prostate cancer: A multicenter exploratory study in China. Urologic oncology, 2026
PubMed 收录了 2 篇关于该疾病、并提及这家医院的论文。
同时上榜：在复旦榜中为 General Surgery #5, Otorhinolaryngology #3, Gastroenterology #4。
-
四川大学华西医院West China Hospital, Sichuan University
复旦专科声誉排行榜 2023
- Urology #2 （并列） https://www.fdygs.com/news2023-1.aspx
国家临床重点专科
- Urology（A 级） https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
同时上榜：在复旦榜中为 General Surgery #3, Thoracic Surgery #4, Otorhinolaryngology #8。
-
北京大学第一医院Peking University First Hospital
复旦专科声誉排行榜 2023
- Urology #2 https://www.fdygs.com/news2023-1.aspx
国家临床重点专科
- Urology（B 级） https://www.pkufh.com/Html/News/Articles/64494.html
已发表研究
- Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer. Prostate cancer and prostatic diseases, 2026
- Predictive value of baseline risk factors and early prostate-specific antigen (PSA) kinetics for achieving deep PSA decline in metastatic hormone-sensitive prostate cancer: implications for treatment intensification. Translational cancer research, 2026
另有 2 项已发表研究
PubMed 收录了 4 篇关于该疾病、并提及这家医院的论文。
同时上榜：在复旦榜中为 传染感染 #9, General Surgery 获提名, Gynecology 获提名。
-
中山大学孙逸仙纪念医院Sun Yat-sen Memorial Hospital, Sun Yat-sen University
复旦专科声誉排行榜 2023
- Urology #4 https://www.fdygs.com/news2023-1.aspx
国家临床重点专科
- Urology（B 级） https://www.gzsys.org.cn/basic/453
已发表研究
- Single-Cell and Spatial Transcriptomics Uncover Immune Dynamics and Cellular Heterogeneity in Benign Prostatic Hyperplasia and Prostate Cancer Transition. MedComm, 2026
- Profiling chimeric RNA in prostate cancer in Chinese cohorts reveals similarities and differences compared to Western populations. iMeta, 2025
另有 1 项已发表研究
PubMed 收录了 3 篇关于该疾病、并提及这家医院的论文。
同时上榜：在复旦榜中为 General Surgery 获提名, Gynecology 获提名, Otorhinolaryngology 获提名。
-
华中科技大学同济医学院附属同济医院Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
复旦专科声誉排行榜 2023
- Urology #5 https://www.fdygs.com/news2023-1.aspx
国家临床重点专科
- Urology（B 级） https://www.tjh.com.cn/contents/934/27291.html
同时上榜：在复旦榜中为 General Surgery #6, Gynecology #2, Respiratory Medicine #8。
-
上海交通大学医学院附属仁济医院Renji Hospital, Shanghai Jiao Tong University School of Medicine
复旦专科声誉排行榜 2023
- Urology #6 https://www.fdygs.com/news2023-1.aspx
国家临床重点专科
- Urology（B 级） https://www.renji.com/gh/article/list/01/01
同时上榜：在复旦榜中为 Gynecology #10, Gastroenterology #1, 核医学 #8。
-
中国医学科学院北京协和医院Peking Union Medical College Hospital
复旦专科声誉排行榜 2023
- Urology #8 https://www.fdygs.com/news2023-1.aspx
同时上榜：在复旦榜中为 General Surgery #1, Gynecology #1, Otorhinolaryngology #4。
-
浙江大学医学院附属第一医院The First Affiliated Hospital, Zhejiang University School of Medicine
复旦专科声誉排行榜 2023
- Urology #9 https://www.fdygs.com/news2023-1.aspx
国家临床重点专科
同时上榜：在复旦榜中为 General Surgery #7, 传染感染 #2, Thoracic Surgery 获提名。
临床试验（在研治疗）
除标准治疗外，针对 Prostate cancer 的临床研究目前可能在中国开放招募受试者。在研治疗尚未获监管机构批准为标准疗法——它们是临床研究，而非常规治疗。每条记录都注明主要研究者与开展研究的医院。如有兴趣，请联系医院了解是否符合条件，并自行决定是否申请。
-
研究 Efficacy and Safety of Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer: A Prospective, Multi-centre Study
- 主要研究者
- Hongqian Guo · Chief physician of Department of Urology
- 医院
- Nanjing Drum Tower Hospital
- 状态
- 招募中
- 登记库
- NCT05753566
-
研究 A Multicenter, Randomized Controlled Clinical Trial Comparing Comprehensive Radiotherapy Versus Primary Tumor Radiotherapy in Oligometastatic Prostate Cancer
- 医院
- Peking University First Hospital
- 状态
- 招募中
- 登记库
- NCT07015138
-
研究 A Phase I, Open-Label, Multicenter, First-in-Human, Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profiles and Preliminary Efficacy of DXC008 in Patients With Prostate Cancer and Other Solid Tumors (Such as Ewing Sarcoma)
- 医院
- Hunan Cancer Hospital
- 状态
- 招募中
- 登记库
- NCT06926283
-
研究 A Phase 1 Study of DEC003M, an Antibody Drug Conjugate Targeting PSMA, for Advanced Stage Prostate Cancer
- 医院
- West China Hospital, Sichuan University
- 状态
- 招募中
- 登记库
- NCT07657806
-
研究 A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer
- 医院
- Chongqing University Cancer Hospital
- 状态
- 招募中
- 登记库
- NCT06095089
另有 50 项已登记研究
-
研究 Extraperitoneal SINgle-port rObotic-assisted Radical Prostatectomy (RARP) Versus Transperitoneal Multi-port RARP in the Treatment Of Prostate Cancer (SINO-TOP)
- 主要研究者
- Ren Shancheng
- 状态
- 招募中
- 登记库
- NCT06238713
-
研究 99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer and Compared With 68Ga-PSMA-11 PET
- 主要研究者
- Xiaoyang Zhang · Principal Investigator
- 医院
- The First Affiliated Hospital of Chongqing Medical University
- 状态
- 招募中
- 登记库
- NCT06419348
-
研究 Safety and Efficacy Study of Hypofractionated Radiotherapy for Localized Prostate Cancer: a Single-arm Clinical Trial
- 主要研究者
- Zhang Huo Jun
- 状态
- 招募中
- 登记库
- NCT06325774
-
研究 Evaluation of Chemotherapy With Adjuvant Docetaxel After Radiotherapy for Localized High Malignant Prostate Cancer: A Prospective Muti-center Non-Randomized Controlled Trial
- 医院
- Peking University First Hospital
- 状态
- 招募中
- 登记库
- NCT06864533
-
研究 Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer
- 主要研究者
- Pengyuan Liu · Research Secretary
- 医院
- Zhejiang Hospital
- 状态
- 招募中
- 登记库
- NCT06249750
-
研究 Development of MR Microstructural Imaging Markers for Prostate Cancer Diagnosis and Investigation of the Associated Molecular Mechanisms
- 医院
- Beijing Hospital
- 状态
- 招募中
- 登记库
- NCT07249281
-
研究 A Phase I Study to Assess the Safety, Tolerability, Radiation Dosimetry and Efficacy of [177Lu] Lu-PSMA-XT in Patients With Metastatic Prostate Cancer
- 主要研究者
- Jinming Zhang · PI
- 医院
- Peking University Cancer Hospital
- 状态
- 招募中
- 登记库
- NCT07096128
-
研究 Delayed PSMA PET/CT Imaging for Diagnosing Clinically Significant Prostate Cancer in Biopsy-Naïve Men With Suspected Prostate Cancer
- 医院
- Shaanxi Provincial People's Hospital
- 状态
- 招募中
- 登记库
- NCT07531329
-
研究 A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate Cancer
- 医院
- Shaanxi Provincial People's Hospital
- 状态
- 招募中
- 登记库
- NCT07474142
-
研究 Plasma Exosomal RNA Signature for Predicting PSMA PET-Defined Bone Metastasis in Prostate Cancer: A Prospective, Multicenter Discovery, Development, and Validation Study
- 医院
- Shaanxi Provincial People's Hospital
- 状态
- 招募中
- 登记库
- NCT07553754
-
研究 A Phase 1, Open-Label, Multicenter, Dose-Escalation and Dose-Expansion Study of ETB-DualNK-01, an Allogeneic Dual-target PSMA/PSCA CAR-NK Cell Product, in Adults With Metastatic Castration-Resistant Prostate Cancer
- 医院
- Peking University Shenzhen Hospital
- 状态
- 招募中
- 登记库
- NCT07641049
-
研究 A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)
- 医院
- Peking University First Hospital
- 状态
- 招募中
- 登记库
- NCT06925737
-
研究 Evaluation of Dosimetry, Safety, Biodistribution and Preliminary Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer
- 医院
- The First Affiliated Hospital of Jinan University
- 状态
- 招募中
- 登记库
- NCT07468708
-
研究 A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer
- 医院
- First Affiliated Hospital of Guangzhou Medical University
- 状态
- 招募中
- 登记库
- NCT07365995
-
研究 An Exploratory Study of the Safety and Efficacy of Genomic Biomarker-guided Neoadjuvant Therapy for Locally Advanced and Oligometastatic Prostate Cancer (SEGNO)
- 医院
- First Affiliated Hospital of Guangzhou Medical University
- 状态
- 招募中
- 登记库
- NCT06387056
-
研究 PET Targeting Acid Phosphatase 3 (ACP3) in Prostate Cancer and Compared With 68Ga-PSMA
- 医院
- First Affiliated Hospital of Guangzhou Medical University
- 状态
- 招募中
- 登记库
- NCT07242014
-
研究 A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer
- 医院
- First Affiliated Hospital of Guangzhou Medical University
- 状态
- 招募中
- 登记库
- NCT06696326
-
研究 A Randomized Phase 2b Study of ZEN003694 in Combination With Enzalutamide Versus Enzalutamide Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- 医院
- Anhui Provincial Hospital
- 状态
- 招募中
- 登记库
- NCT04986423
-
研究 A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T Cell Engaging Agent Targeting Human Kallikrein 2, With or Without JNJ-87189401, a PSMA-CD28 Costimulatory Agent, Plus Best Supportive Care Versus Best Supportive Care for Late-line Metastatic Castration-resistant Prostate Cancer
- 医院
- Peking University First Hospital
- 状态
- 招募中
- 登记库
- NCT07164443
-
研究 A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-engaging Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
- 医院
- Peking University Cancer Hospital
- 状态
- 招募中
- 登记库
- NCT07225946
-
研究 The Addictive Diagnostic Value of Apparent Diffusion Coefficients to PI-RADS 3-5 of Biparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer
- 主要研究者
- XiaoJun · Professor, Chief Physician
- 医院
- First Affiliated Hospital of Guangzhou Medical University
- 状态
- 招募中
- 登记库
- NCT06737588
-
研究 An Open, Multicenter Phase Ib/II Study on the Safety, Tolerability and Efficacy of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
- 医院
- Second Affiliated Hospital of Harbin Medical University
- 状态
- 招募中
- 登记库
- NCT06568094
-
研究 Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer
- 医院
- The First Affiliated Hospital of Fujian Medical University
- 状态
- 招募中
- 登记库
- NCT07056790
-
研究 The Enhancement of Diagnostic and Grading Efficacy of Prostate Cancer by New MRI Sequences: A Prospective Observational Study Based on New MRI Sequences in a Single Center
- 医院
- First Affiliated Hospital of Guangzhou Medical University
- 状态
- 招募中
- 登记库
- NCT07552285
-
研究 Rezvilutamide Monotherapy as Adjuvant Treatment for Patients With High Recurrence Risk After Radical Prostatectomy: A Prospective, Multicenter, Single-Arm Study
- 主要研究者
- Hongqian Guo · Chief Physician, Professor, Director of Urology
- 医院
- Nanjing Drum Tower Hospital
- 状态
- 招募中
- 登记库
- NCT07711314
-
研究 A Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of HS-20093 or SHR2554 Tablets in Combination With Novel Hormonal Agents in Participants With Metastatic Prostate Cancer
- 医院
- Nanjing Drum Tower Hospital
- 状态
- 招募中
- 登记库
- NCT07230106
-
研究 Diagnostic Value of MRI-targeted Plus Index-lesion-ipsilaterally Systematic Biopsy for Biopsy-naive Men At Risk of Prostate Cancer: a Prospective, Multicenter, Paired, Non-inferiority Trial
- 主要研究者
- Hongqian Guo · Chief physician
- 医院
- Nanjing Drum Tower Hospital
- 状态
- 招募中
- 登记库
- NCT06584279
-
研究 A Prospective, Multicenter, Open-Label, Randomized, Parallel-Group, Noninferiority Trial of MRI/Ultrasound Cognitive Fusion Targeted Biopsy Combined With Ipsilateral Versus Bilateral Systematic Biopsy for Prostate Cancer Diagnosis
- 医院
- Nanjing Drum Tower Hospital
- 状态
- 招募中
- 登记库
- NCT07795723
-
研究 Neoadjuvant ADT +/- Darolutamide Followed by Radical Prostatectomy for High-risk Prostate Cancer: a Randomized, Open Label Trial
- 状态
- 招募中
- 登记库
- NCT06575257
-
研究 Serial PSMA PET for Treatment Response Monitoring in Newly Diagnosed Clinically Significant, Treatment-Naïve Prostate Cancer - A Prospective, Multicenter Study
- 医院
- Shaanxi Provincial People's Hospital
- 状态
- 招募中
- 登记库
- NCT07553780
-
研究 Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
- 医院
- Shaanxi Provincial People's Hospital
- 状态
- 招募中
- 登记库
- NCT07492927
-
研究 Post-marketing Clinical Study of Transrectal High-intensity Focused Ultrasound for Localized Prostate Cancer
- 医院
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
- 状态
- 招募中
- 登记库
- NCT06362577
-
研究 Systemic Therapy Combined With Cytoreductive Prostatectomy for the Treatment of de Novo Poly-metastatic Hormone Sensitive Prostate Cancer: A Prospective, Open-label Randomized Controlled Trial
- 主要研究者
- Liang Dong · Associate Research Fellow
- 医院
- Renji Hospital, Shanghai Jiao Tong University School of Medicine
- 状态
- 招募中
- 登记库
- NCT06306612
-
研究 A Head-to-Head Comparison of Targeted and Perilesional Biopsy Versus Combination of Sextant-Systematic Biopsy and Targeted Biopsy for Prostate Cancer Diagnosis: A Randomized Controlled Trial
- 主要研究者
- LIU Yi · Associate chief physician
- 医院
- Peking University First Hospital
- 状态
- 招募中
- 登记库
- NCT07460843
-
研究 Comparison of MRI Artificial Intelligence-guided Cognitive Fusion-targeted Biopsy Versus Routine Cognitive Fusion-targeted Prostate Biopsy in Prostate Cancer Diagnosis: a Multicenter Randomized Controlled Clinical Trial
- 主要研究者
- LIU Yi · Associate chief physician
- 医院
- Peking University First Hospital
- 状态
- 招募中
- 登记库
- NCT06392737
-
研究 Evaluation of Perilesional Biopsy in Diagnosis of Prostate Cancer: a Multicenter Randomized Controlled Trial
- 主要研究者
- LIU Yi · Associate chief physician
- 医院
- Peking University First Hospital
- 状态
- 招募中
- 登记库
- NCT06482645
-
研究 A Prospective, Open-label, Dose-Escalation, Single-Center Study to Evaluate the Safety, Biodistribution/Dosimetry and Preliminary Efficacy of 161Tb-LNC1011 in Patients With Metastatic Castration-Resistant Prostate Cancer
- 医院
- Peking Union Medical College Hospital
- 状态
- 尚未招募
- 登记库
- NCT07381582
-
研究 An Exploratory Clinical Study of Rezvilutamide as Adjuvant Therapy for High-Risk Patients After Radical Prostatectomy
- 医院
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- 状态
- 尚未招募
- 登记库
- NCT07444983
-
研究 A Prospective Exploratory Phase II Study on the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer With Darxicilib in Combination With Abiraterone Acetate (II)
- 医院
- Qilu Hospital of Shandong University
- 状态
- 尚未招募
- 登记库
- NCT06500247
-
研究 A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer
- 医院
- Chinese PLA General Hospital
- 状态
- 尚未招募
- 登记库
- NCT07641855
-
研究 An Open-Label, Single-Arm, Exploratory Study to Evaluate the Safety and Preliminary Efficacy of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- 主要研究者
- Ren Shancheng
- 状态
- 尚未招募
- 登记库
- NCT07389187
-
研究 An Open-Label, Exploratory Study to Evaluate the Safety and Preliminary Efficacy of LC-K76 in Combination With Endocrine Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer
- 主要研究者
- Ren Shancheng
- 状态
- 尚未招募
- 登记库
- NCT07389174
-
研究 Prognostic Study of Prostate Cancer Via Dynamic Change of PSA in Peritoneal Drainage Fluid After Radical Prostatectomy
- 主要研究者
- Liu Cheng · Principal Investigator
- 医院
- Shanghai General Hospital
- 状态
- 尚未招募
- 登记库
- NCT06608225
-
研究 A Multicenter, Prospective, Single-Arm Clinical Trial Evaluating MRI/Ultrasound Fusion Targeted Biopsy With Intraoperative Frozen Section and Rapid Immunohistochemistry Followed by Immediate Laparoscopic Radical Prostatectomy in Patients With High-Risk Prostate Cancer Identified by the USTC Model
- 主要研究者
- Tao Tao, MD · Associate professor, Associate chief physician
- 医院
- Anhui Provincial Hospital
- 状态
- 尚未招募
- 登记库
- NCT07709338
-
研究 A Study to Evaluate the Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center Study
- 主要研究者
- Yong He · Director, Department of Nuclear Medicine, Zhongnan Hospital of Wuhan University
- 医院
- Zhongnan Hospital of Wuhan University
- 状态
- 尚未招募
- 登记库
- NCT07830212
-
研究 Application of Quantum Detection-Driven Artificial Intelligence Algorithms for Single-Molecule cfDNA Characterization in the Early Diagnosis of Prostate Cancer
- 主要研究者
- Ren Shancheng · Professor, Chief of Urology
- 医院
- West China Hospital, Sichuan University
- 状态
- 尚未招募
- 登记库
- NCT07238959
-
研究 A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate the Diagnostic Efficacy and Safety of INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment
- 医院
- Beijing Chao-Yang Hospital, Capital Medical University
- 状态
- 尚未招募
- 登记库
- NCT06922929
-
研究 A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate the Diagnostic Efficacy and Safety of INR101 Injection for PET/CT Imaging in Detecting Preoperative Pelvic Lymph Node Metastasis in Patients With Prostate Cancer
- 医院
- Beijing Chao-Yang Hospital, Capital Medical University
- 状态
- 尚未招募
- 登记库
- NCT06922903
-
研究 Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer: a Phase 2, Multicenter, Open-label, Randomized Controlled Trial
- 主要研究者
- Yung NA · Clinical Assistant Professor
- 医院
- Huashan Hospital
- 状态
- 尚未招募
- 登记库
- NCT07310433
-
研究 Radioactive Counts From PSMA PET/CT-Targeted Biopsy Specimens for Real-time Diagnosis of Prostate Cancer: A Prospective Study
- 主要研究者
- LIU Yi · Principal Investigator
- 医院
- Peking University First Hospital
- 状态
- 尚未招募
- 登记库
- NCT07709403
本页仅分享公开登记的研究信息，不推荐也不鼓励参加任何研究。参加完全自愿，且未经批准治疗的风险尚不明确；请直接联系医院了解入组条件与知情同意细节。
拥有国家临床重点专科记录的医院
显示医院记录 30 家拥有重点专科记录的医院
每一行都是在某疾病所归属专科中拥有国家临床重点专科记录的医院。这是对已发布名单的记录，既不构成推荐，也不是排名。
30 家拥有匹配的国家临床重点专科记录的医院。
以中文写出的数值按来源原样引用。
患者报告的情况
仅为汇总数据：一项全国性结果，附其来源与所指年份。这不是患者证言，也不是关于某一个人的陈述。
据 National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号)（2023）报道：National inpatient satisfaction / outpatient satisfaction — 95.42 / 93.95 score, 0-100。
National aggregate across the 2,168 tertiary public hospitals that took part in the national performance monitoring (all conditions combined; not disease-specific, not hospital-specific).
来源：National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) — https://www.gov.cn/zhengce/zhengceku/202503/content_7016208.htm — 2023 — A 级
关于该疾病的问题
我们不能提供医疗建议，但可以回答关于本页以及在中国安排就医的问题。
ICD 编码
显示编码表 1 个 ICD 编码
| 版本 | 编码 | 该版本中的名称 |
|---|---|---|
| ICD-10-WHO | C61 | Malignant neoplasm of prostate |
各行为该疾病的 WHO ICD-10 条目，按原样引用。
来源与证据
- 来源 URL
- https://wjw.fujian.gov.cn/xxgk/fgwj/zxwj/201904/P020190412506737868905.xlsx
- 来源协议
- https
- 来源类型
- 省级卫生健康委员会
- 证据等级
- A ——由卫生健康委员会、国家级研究机构或大学所述
- 获取日期
- 2026-09-24